In spite of the multiple deaths from the Heparin catastrophe discovered in March, the FDA has been working to place inspectors on the ground in China. A permanent office is scheduled to open in October. So what does this mean for your operations in China? Are your manufacturing facilities in compliance? Will your staff even be able to communicate with inspectors?

In a new BioWorld Today and Medical Device Daily audio conference, speaker Joan McEntee, Shareholder and Chair of the China Group at Baker, Donelson, Bearman, Caldwell & Berkowitz, provides strategic guidance on the changing face of FDA-regulated manufacturing in China.

"FDA Inspections in China: Your Manufacturing Operations Are in the Crosshairs—Be Ready" is just $349 per listening site. Scheduled for August 5th, from 1-2:30 p.m., it includes presentation handouts and a half-hour Q&A session with the speaker. A conference CD (MP3) is available. Please call 800-688-2421 or 404-262-5474 and mention conference code T08505.